Short-Course radiation may boost immunotherapy and chemo for stomach cancer
NCT ID NCT07674342
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This study investigates whether adding a short course of radiotherapy before surgery, alongside a PD-1 inhibitor (serplulimab) and chemotherapy (SOX), can improve outcomes for people with locally advanced upper stomach or gastroesophageal junction cancer. Participants are randomly assigned to receive either the full combination (radiotherapy plus drugs) or drugs alone before surgery, followed by additional drug therapy after surgery. The main goal is to see if the combination leads to a complete disappearance of cancer cells in the removed tissue.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Serplulimab (PD-1 inhibitor) combined with SOX chemotherapy (S-1, oxaliplatin), with or without short-course radiotherapy
What this could lead to
If successful, this approach could improve the chance of complete tumor removal and long-term control for people with locally advanced stomach cancer.
What could go wrong
This is a mid-stage trial with 146 participants, so results may not apply to all patients. Adding radiotherapy may increase side effects, and the treatment involves chemotherapy and immunotherapy, which can cause significant adverse reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED PROXIMAL GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tongji Hospital, Huazhong University of Science and Technology
Wuhan, Hubei, 430030, China
Contact Phone: •••-•••-•••• Email: •••••@•••••